• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams

    6/18/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email

    WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor®. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.

    "This isn't just an expansion—it's execution," said Jack Ross, CEO of Synergy CHC Corp. "Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We're building brand equity globally without the overhead—exactly how growth should look in 2025."

    The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots—without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.

    Key Highlights for Investors:

    • $2M in licensing secured
    • Additional revenue potential through royalties
    • Scalable, asset-light growth strategy
    • Brain health market expected to top $20B by 2030

    With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola's global beverage team, reinforcing the Company's commitment to accelerated growth and operational precision.

    About Synergy CHC Corp.

    Synergy CHC Corp. (NASDAQ: SNYR) is a next-generation consumer health and wellness company. Its flagship brands include FOCUSfactor®, a clinically tested brain health supplement, and Flat Tummy®, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.

    Investor Relations

    Gateway Group

    Cody Slach, Greg Robles

    949.574.3860

    [email protected]



    Primary Logo

    Get the next $SNYR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor® Focus + Energy

    WESTBROOK, Maine, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced a major retail distribution win for its FOCUSfactor Focus + Energy beverage line through EG America, the 6th largest convenience store chain in the United States. With more than 1,600 locations nationwide under banners including Cumberland Farms, Certified Oil, Kwik Shop, Loaf ‘N Jug, Minit Mart, Tom Thumb, and Turkey Hill, EG America is recognized for innovation in convenience retail and premium consumer offerings. The Q4 2025 rollout will significantly expand FOCUSfactor's footprint in the fast-growing functio

    8/18/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

    WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025. "We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Revenue, gross profit, net income and earnings per share all grew year-over-year, reflecting our continued focus on disciplined execution and profitable growth." "We also made significant progress across our strategic priorities, including expanding the global footprint of our FOCUSfactor brand through a licensing agreemen

    8/14/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, before the open of market trading. In conjunction with reporting second quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

    7/31/25 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    Synergy CHC Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Synergy CHC Corp. (0001562733) (Filer)

    8/18/25 9:14:50 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form S-1 filed by Synergy CHC Corp.

    S-1 - Synergy CHC Corp. (0001562733) (Filer)

    8/15/25 4:15:47 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Synergy CHC Corp.

    10-Q - Synergy CHC Corp. (0001562733) (Filer)

    8/14/25 8:05:51 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Large owner Knight Therapeutics Inc

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/13/25 4:05:05 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

    WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025. "We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Revenue, gross profit, net income and earnings per share all grew year-over-year, reflecting our continued focus on disciplined execution and profitable growth." "We also made significant progress across our strategic priorities, including expanding the global footprint of our FOCUSfactor brand through a licensing agreemen

    8/14/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, July 31, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that it plans to release financial results for the second quarter ended June 30, 2025, on Thursday, August 14, 2025, before the open of market trading. In conjunction with reporting second quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

    7/31/25 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

    WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

    5/15/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

    WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

    5/29/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care